Effect of miR-19a on lipid catabolism in hepatocyte LO2
TIAN Xiao-ling1, LIN Feng-ping1, LI Wei-min2, LIU Xiu-fen3
1. Department of Endocrinology, Xianning Central Hospital, Xianning 437100, China;
2. Department of Internal Medicine, Hubei University of Science and Technology, Xianning 437100, China;
3. Department of Pharmacology, Hubei University of Science and Technology, Xianning 437100, China
AIM: To observe the effect of microRNA-19a (miR-19a) on the lipid catabolism of hepatocyte LO2, and to explore the potential mechanism. METHODS: miR-19a was over-expressed or silenced by transfection of miR-19a mimics or miR-19a inhibitor into LO2 cells, then the mRNA level of miR-19a was detected by real-time PCR. The potential target of miR-19a was found by the method of bioinformatics through internet website. The effect of miR-19a on the 3' UTR of peroxisome proliferator-activated receptor α (PPARα) was measured by dual luciferase reporter assay, and the protein level of PPARα and its 2 major downstream rate-limiting enzymes involved in lipid catabolism, acyl-coenzyme a dehydrogenase (ACADM) and carnitine palmitoyltransferase 1A (CPT1A), were detected by Western blotting. Meanwhile, the effect of miR-19a on the generation of ketone body was measured by beta-hydroxybutyric acid (β-OHB) detection assay. RESULTS: The mRNA level of miR-19a was dramatically elevated by the transfection of miR-19a mimics, and sharply decreased by the transfection of miR-19a inhibitor (P<0.05). PPARα was found as a potential target of miR-19a, and dual luciferase reporter assay and Western blotting confirmed the regulatory effect of miR-19a on the expression of PPARα, with the protein level changes of ACADM and CPT1A. miR-19a mimics down-regulated, while miR-19a inhibitor up-regulated the concentration of β-OHB in LO2 cells (P<0.05). CONCLUSION: miR-19a regulates the lipid catabolism of hepatocytes by targeting the PPARα and its 2 downstream rate-limiting enzymes.
Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer[J]. World J Gastroenterol, 2014, 20(34):12007-12017.
[2]
Neves VJ, Fernandes T, Roque FR, et al. Exercise training in hypertension: Role of microRNAs[J]. World J Cardiol, 2014, 6(8):713-727.
[3]
Wegner M, Neddermann D, Piorunska-Stolzmann M, et al. Role of epigenetic mechanisms in the development of chronic complications of diabetes[J]. Diabetes Res Clin Pract, 2014, 105(2):164-175.
[4]
Olive V, Li Q, He L. miR-17-92: a polycistronic oncomir with pleiotropic functions[J]. Immunol Rev, 2013, 253(1):158-166.
[5]
Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease[J]. Cell Death Differ, 2013, 20(12):1603-1614.
[6]
Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease[J]. World J Hepatol, 2014, 6(8):570-579.
[7]
Zeng L, Tang WJ, Yin JJ, et al. Signal transductions and nonalcoholic fatty liver: a mini-review[J]. Int J Clin Exp Med, 2014, 7(7):1624-1631.
[8]
Leal J, Ades AE, Wordsworth S, et al. Regional differences in the frequency of the c.985A>G ACADM mutation: findings from a meta-regression of genotyping and screening studies[J]. Clin Genet, 2014, 85(3):253-259.
[9]
Gagnon F, Assi D, Carrié A, et al. Robust validation of methylation levels association at CPT1A locus with lipid plasma levels[J]. J Lipid Res, 2014, 55(7):1189-1191.
